Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2014

Open Access 01-12-2014 | Research

Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma

Authors: Kenjiro Kimura, Ryosuke Amano, Bunzo Nakata, Sadaaki Yamazoe, Keiichiro Hirata, Akihiro Murata, Kotaro Miura, Kohei Nishio, Toshiki Hirakawa, Masaichi Ohira, Kosei Hirakawa

Published in: World Journal of Surgical Oncology | Issue 1/2014

Login to get access

Abstract

Background

Clinical factors determining short-term survival after pancreatectomy have been well studied, but factors predicting long-term survival with curative resection are poorly understood in pancreatic carcinoma. Our objective was to identify clinical and pathological features of five-year disease-free survivors after surgical resection of pancreatic adenocarcinoma.

Methods

The clinical and pathological data from 147 patients who underwent a potentially curative resection for pancreatic adenocarcinoma at our institution between 1988 and 2012 were retrospectively analyzed.

Results

Of 147 patients, 18 survived for more than five years after surgery without disease recurrence. A univariate analyses demonstrated that: two or fewer lymph node metastases (P = 0.014), a preoperative serum carbohydrate antigen 19-9 (CA19-9) level of 40 U/mL or less (P = 0.0018), an absence of intrapancreatic nerve invasion (P = 0.028), and undergoing an R0 resection (P = 0.011) were significantly associated with five-year survival. A logistic regression model identified the following independent cancer-related predictors of five-year survivors: having two or fewer lymph node metastases (odds ratio (OR): 6.02; 95% confidence interval (CI): 1.08 to 112.98; P = 0.0385), a preoperative serum CA19-9 level of 40 U/mL or less (OR: 5.02; 95% CI: 1.68 to 16.48; P = 0.0036), and undergoing an R0 resection (OR: 3.63; 95% CI: 1.12 to 14.28; P = 0.0316).

Conclusions

We conclude that number of lymph node metastases being two or less, a preoperative serum CA19-9 level of 40 U/mL or less, and undergoing an R0 resection may be independent predictive factors to identify actual five-year survivors after pancreatectomy for pancreatic adenocarcinoma.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62: 10-29. 10.3322/caac.20138.CrossRefPubMed Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62: 10-29. 10.3322/caac.20138.CrossRefPubMed
2.
go back to reference Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K: Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas. 2004, 28: 219-230. 10.1097/00006676-200404000-00002.CrossRefPubMed Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K: Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas. 2004, 28: 219-230. 10.1097/00006676-200404000-00002.CrossRefPubMed
3.
go back to reference Zuckerman DS, Ryan DP: Adjuvant therapy for pancreatic cancer: a review. Cancer. 2008, 112: 243-249. 10.1002/cncr.23174.CrossRefPubMed Zuckerman DS, Ryan DP: Adjuvant therapy for pancreatic cancer: a review. Cancer. 2008, 112: 243-249. 10.1002/cncr.23174.CrossRefPubMed
4.
go back to reference Zacharias T, Jaeck D, Oussoultzoglou E, Neuville A, Bachellier P: Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J Gastrointest Surg. 2007, 11: 350-356. 10.1007/s11605-007-0113-3.CrossRefPubMed Zacharias T, Jaeck D, Oussoultzoglou E, Neuville A, Bachellier P: Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J Gastrointest Surg. 2007, 11: 350-356. 10.1007/s11605-007-0113-3.CrossRefPubMed
5.
go back to reference Lim JE, Chien MW, Earle CC: Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003, 237: 74-85. 10.1097/00000658-200301000-00011.PubMedCentralCrossRefPubMed Lim JE, Chien MW, Earle CC: Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003, 237: 74-85. 10.1097/00000658-200301000-00011.PubMedCentralCrossRefPubMed
6.
go back to reference Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, Gullerud RE, Donohue JH, Nagorney DM, Farnell MB: Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?. Ann Surg. 2008, 247: 456-462. 10.1097/SLA.0b013e3181613142.CrossRefPubMed Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, Gullerud RE, Donohue JH, Nagorney DM, Farnell MB: Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?. Ann Surg. 2008, 247: 456-462. 10.1097/SLA.0b013e3181613142.CrossRefPubMed
7.
go back to reference Ferrone CR, Brennan MF, Gonen M, Coit DG, Fong Y, Chung S, Tang L, Klimstra D, Allen PJ: Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg. 2008, 12: 701-706. 10.1007/s11605-007-0384-8.CrossRefPubMed Ferrone CR, Brennan MF, Gonen M, Coit DG, Fong Y, Chung S, Tang L, Klimstra D, Allen PJ: Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg. 2008, 12: 701-706. 10.1007/s11605-007-0384-8.CrossRefPubMed
8.
go back to reference Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, Buchler MW, Werner J: Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg. 2011, 254: 311-319. 10.1097/SLA.0b013e31821fd334.CrossRefPubMed Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, Buchler MW, Werner J: Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg. 2011, 254: 311-319. 10.1097/SLA.0b013e31821fd334.CrossRefPubMed
9.
go back to reference Waraya M, Yamashita K, Katagiri H, Ishii K, Takahashi Y, Furuta K, Watanabe M: Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol. 2009, 16: 1231-1240. 10.1245/s10434-009-0415-7.CrossRefPubMed Waraya M, Yamashita K, Katagiri H, Ishii K, Takahashi Y, Furuta K, Watanabe M: Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol. 2009, 16: 1231-1240. 10.1245/s10434-009-0415-7.CrossRefPubMed
10.
go back to reference Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL: Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006, 24: 2897-2902. 10.1200/JCO.2005.05.3934.CrossRefPubMed Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL: Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006, 24: 2897-2902. 10.1200/JCO.2005.05.3934.CrossRefPubMed
11.
go back to reference Hallemeier CL, Botros M, Corsini MM, Haddock MG, Gunderson LL, Miller RC: Preoperative CA 19–9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy. Am J Clin Oncol. 2011, 34: 567-572. 10.1097/COC.0b013e3181f946fc.CrossRefPubMed Hallemeier CL, Botros M, Corsini MM, Haddock MG, Gunderson LL, Miller RC: Preoperative CA 19–9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy. Am J Clin Oncol. 2011, 34: 567-572. 10.1097/COC.0b013e3181f946fc.CrossRefPubMed
12.
go back to reference Adham M, Jaeck D, Le Borgne J, Oussoultzouglou E, Chenard-Neu MP, Mosnier JF, Scoazec JY, Mornex F, Partensky C: Long-term survival (5–20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions. Pancreas. 2008, 37: 352-357. 10.1097/MPA.0b013e31818166d2.CrossRefPubMed Adham M, Jaeck D, Le Borgne J, Oussoultzouglou E, Chenard-Neu MP, Mosnier JF, Scoazec JY, Mornex F, Partensky C: Long-term survival (5–20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions. Pancreas. 2008, 37: 352-357. 10.1097/MPA.0b013e31818166d2.CrossRefPubMed
13.
go back to reference Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, Strasberg S, Hanna S, Taylor B, Langer B, Gallinger S: Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg. 2004, 198: 722-731. 10.1016/j.jamcollsurg.2004.01.008.CrossRefPubMed Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, Strasberg S, Hanna S, Taylor B, Langer B, Gallinger S: Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg. 2004, 198: 722-731. 10.1016/j.jamcollsurg.2004.01.008.CrossRefPubMed
14.
go back to reference Shimada K, Sakamoto Y, Nara S, Esaki M, Kosuge T, Hiraoka N: Analysis of 5-year survivors after a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma. World J Surg. 2010, 34: 1908-1915. 10.1007/s00268-010-0570-9.CrossRefPubMed Shimada K, Sakamoto Y, Nara S, Esaki M, Kosuge T, Hiraoka N: Analysis of 5-year survivors after a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma. World J Surg. 2010, 34: 1908-1915. 10.1007/s00268-010-0570-9.CrossRefPubMed
15.
go back to reference Gordon TA, Burleyson GP, Tielsch JM, Cameron JL: The effects of regionalization on cost and outcome for one general high-risk surgical procedure. Ann Surg. 1995, 221: 43-49. 10.1097/00000658-199501000-00005.PubMedCentralCrossRefPubMed Gordon TA, Burleyson GP, Tielsch JM, Cameron JL: The effects of regionalization on cost and outcome for one general high-risk surgical procedure. Ann Surg. 1995, 221: 43-49. 10.1097/00000658-199501000-00005.PubMedCentralCrossRefPubMed
16.
go back to reference Ho V, Heslin MJ: Effect of hospital volume and experience on in-hospital mortality for pancreaticoduodenectomy. Ann Surg. 2003, 237: 509-514.PubMedCentralPubMed Ho V, Heslin MJ: Effect of hospital volume and experience on in-hospital mortality for pancreaticoduodenectomy. Ann Surg. 2003, 237: 509-514.PubMedCentralPubMed
17.
go back to reference Sosa JA, Bowman HM, Gordon TA, Bass EB, Yeo CJ, Lillemoe KD, Pitt HA, Tielsch JM, Cameron JL: Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg. 1998, 228: 429-438. 10.1097/00000658-199809000-00016.PubMedCentralCrossRefPubMed Sosa JA, Bowman HM, Gordon TA, Bass EB, Yeo CJ, Lillemoe KD, Pitt HA, Tielsch JM, Cameron JL: Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg. 1998, 228: 429-438. 10.1097/00000658-199809000-00016.PubMedCentralCrossRefPubMed
18.
go back to reference SLaW C: TMN Classification of Malignant Tumours. 2002, New Jersey: John Wiley and Sons Ltd, 6 SLaW C: TMN Classification of Malignant Tumours. 2002, New Jersey: John Wiley and Sons Ltd, 6
19.
go back to reference Bosman ESJ FT, Lakhani SR, Hiroko O: WHO Classification of Tumours of the Digestive System. 2010, Lyon: International Agency for Research on Cancer Bosman ESJ FT, Lakhani SR, Hiroko O: WHO Classification of Tumours of the Digestive System. 2010, Lyon: International Agency for Research on Cancer
20.
go back to reference Japanese Pancreas Society: General Rules for the Study of Pancreatic Cancer. 2009, Tokyo: Kanehara-syuppan, 6 Japanese Pancreas Society: General Rules for the Study of Pancreatic Cancer. 2009, Tokyo: Kanehara-syuppan, 6
21.
go back to reference Meyer W, Jurowich C, Reichel M, Steinhauser B, Wunsch PH, Gebhardt C: Pathomorphological and histological prognostic factors in curatively resected ductal adenocarcinoma of the pancreas. Surg Today. 2000, 30: 582-587. 10.1007/s005950070096.CrossRefPubMed Meyer W, Jurowich C, Reichel M, Steinhauser B, Wunsch PH, Gebhardt C: Pathomorphological and histological prognostic factors in curatively resected ductal adenocarcinoma of the pancreas. Surg Today. 2000, 30: 582-587. 10.1007/s005950070096.CrossRefPubMed
22.
go back to reference Pantalone D, Ragionieri I, Nesi G: Improved survival in small pancreatic cancer. Dig Surg. 2001, 18: 41-46. 10.1159/000050095.CrossRefPubMed Pantalone D, Ragionieri I, Nesi G: Improved survival in small pancreatic cancer. Dig Surg. 2001, 18: 41-46. 10.1159/000050095.CrossRefPubMed
23.
go back to reference Pongprasobchai S, Pannala R, Smyrk TC, Bamlet W, Pitchumoni S, Ougolkov A, de Andrade M, Petersen GM, Chari ST: Long-term survival and prognostic indicators in small (<or = 2 cm) pancreatic cancer. Pancreatology. 2008, 8: 587-592. 10.1159/000161009.PubMedCentralCrossRefPubMed Pongprasobchai S, Pannala R, Smyrk TC, Bamlet W, Pitchumoni S, Ougolkov A, de Andrade M, Petersen GM, Chari ST: Long-term survival and prognostic indicators in small (<or = 2 cm) pancreatic cancer. Pancreatology. 2008, 8: 587-592. 10.1159/000161009.PubMedCentralCrossRefPubMed
24.
go back to reference Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, Dooley WC, Coleman J, Pitt HA: Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg. 1995, 221: 721-731. 10.1097/00000658-199506000-00011. discussion 731–723PubMedCentralCrossRefPubMed Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, Dooley WC, Coleman J, Pitt HA: Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg. 1995, 221: 721-731. 10.1097/00000658-199506000-00011. discussion 731–723PubMedCentralCrossRefPubMed
25.
go back to reference Huebner M, Kendrick M, Reid-Lombardo KM, Que F, Therneau T, Qin R, Donohue J, Nagorney D, Farnell M, Sarr M: Number of lymph nodes evaluated: prognostic value in pancreatic adenocarcinoma. J Gastrointest Surg. 2012, 16: 920-926. 10.1007/s11605-012-1853-2.CrossRefPubMed Huebner M, Kendrick M, Reid-Lombardo KM, Que F, Therneau T, Qin R, Donohue J, Nagorney D, Farnell M, Sarr M: Number of lymph nodes evaluated: prognostic value in pancreatic adenocarcinoma. J Gastrointest Surg. 2012, 16: 920-926. 10.1007/s11605-012-1853-2.CrossRefPubMed
26.
go back to reference Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB: Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009, 16: 836-847. 10.1245/s10434-008-0295-2.PubMedCentralCrossRefPubMed Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB: Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009, 16: 836-847. 10.1245/s10434-008-0295-2.PubMedCentralCrossRefPubMed
27.
go back to reference Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zulke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H: Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013, 310: 1473-1481. 10.1001/jama.2013.279201.CrossRefPubMed Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zulke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H: Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013, 310: 1473-1481. 10.1001/jama.2013.279201.CrossRefPubMed
28.
go back to reference Uesaka K, Fukutomi A, Boku N, Kanemoto M, Konishi I, Matsumoto Y, Shimizu S: Randomized phase 3 trial of adjuvant chemotherapy with gemcitabine vs. S-1 for resected pancreatic cancer (JASPAC-01 study). J Clin Oncol. 2013, 31 (4s): abst145- Uesaka K, Fukutomi A, Boku N, Kanemoto M, Konishi I, Matsumoto Y, Shimizu S: Randomized phase 3 trial of adjuvant chemotherapy with gemcitabine vs. S-1 for resected pancreatic cancer (JASPAC-01 study). J Clin Oncol. 2013, 31 (4s): abst145-
29.
go back to reference Reni M: Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?. World J Gastroenterol. 2010, 16: 4883-4887. 10.3748/wjg.v16.i39.4883.PubMedCentralCrossRefPubMed Reni M: Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?. World J Gastroenterol. 2010, 16: 4883-4887. 10.3748/wjg.v16.i39.4883.PubMedCentralCrossRefPubMed
30.
go back to reference Festa V, Andriulli A, Valvano MR, Uomo G, Perri F, Andriulli N, Corrao S, Koch M: Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: a meta-analytical evaluation of prospective studies. JOP. 2013, 14: 618-625.PubMed Festa V, Andriulli A, Valvano MR, Uomo G, Perri F, Andriulli N, Corrao S, Koch M: Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: a meta-analytical evaluation of prospective studies. JOP. 2013, 14: 618-625.PubMed
Metadata
Title
Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma
Authors
Kenjiro Kimura
Ryosuke Amano
Bunzo Nakata
Sadaaki Yamazoe
Keiichiro Hirata
Akihiro Murata
Kotaro Miura
Kohei Nishio
Toshiki Hirakawa
Masaichi Ohira
Kosei Hirakawa
Publication date
01-12-2014
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-12-360

Other articles of this Issue 1/2014

World Journal of Surgical Oncology 1/2014 Go to the issue